increased adenocarcinoma incidence_Vhl<tm1.1Wkr>/Vhl<+>

http://metadb.riken.jp/0009308I129S4SvJaeC57BL6Vhltm11WkrVhlVhltm11WkrVhl

increased adenocarcinoma incidence_Vhl<tm1.1Wkr>/Vhl<+>

表現型アノテーション

MGI marker

http://metadb.riken.jp/db/mgi_rdf/variant_of

• von Hippel-Lindau tumor suppressor
  http://metadb.riken.jp/db/mgi_rdf/MGI:103223

遺伝子型

http://metadb.riken.jp/db/mgi_rdf/allele_composition

• Vhl<tm1.1Wkr>/Vhl<+>

アレルシンボル

http://metadb.riken.jp/db/mgi_rdf/allele_symbol

• Vhl<tm1.1Wkr>|Vhl<+>

遺伝的背景

http://metadb.riken.jp/db/mgi_rdf/genetic_background

• involves: 129S4/SvJae * C57BL/6

MP annotation

http://metadb.riken.jp/db/bioresource_schema/brs_indicatesPhenotype

• increased adenocarcinoma incidence
  http://purl.obolibrary.org/obo/MP_0009308

文献

http://purl.org/net/cito/citesAsAuthority

• C M. Lee, et.al., VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo., Oncogene, 2009, 28
  http://rdf.ncbi.nlm.nih.gov/pubmed/19252526